Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 2

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Down Syndrome 1

Interventions

pembrolizumab 80Carboplatin 73Paclitaxel 58Cisplatin 58Specimen Handling 56Magnetic Resonance Spectroscopy 56Gemcitabine 48Docetaxel 37Dexamethasone 37Oxaliplatin 34Fluorouracil 33Bevacizumab 33Pemetrexed 32Leucovorin 32Doxorubicin 32Cyclophosphamide 31durvalumab 29Radiotherapy 29Radiation 28Capecitabine 28Rituximab 25Letrozole 25Etoposide 24Nivolumab 23Irinotecan 23Vincristine 22Taxes 21Lenalidomide 21Prednisone 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 30 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡